Tirzepatide — Vendor Pricing & Purity Guide
Research Overview
Tirzepatide is a dual GLP-1/GIP receptor agonist developed by Eli Lilly. It is FDA-approved as Mounjaro (for type 2 diabetes) and Zepbound (for chronic weight management). Tirzepatide is the first approved medication to activate both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors, representing an evolution beyond single-target GLP-1 agonists like semaglutide.
The dual-agonist mechanism produces complementary metabolic effects. GLP-1 activation suppresses appetite, slows gastric emptying, and stimulates insulin secretion. GIP activation enhances the insulin response further and may independently promote fat metabolism and improve lipid profiles. The combined effect produced the largest weight loss results ever seen in an obesity drug trial — surpassing semaglutide in head-to-head studies.
Tirzepatide has rapidly become one of the most commercially significant drugs in pharmaceutical history, with peak sales projected to exceed $25 billion annually across indications. Research-grade tirzepatide is available from peptide vendors, though like semaglutide, it differs from the pharmaceutical product in manufacturing quality and oversight.
Key Research Findings
- •SURMOUNT-1 trial: 22.5% mean weight loss at the highest dose (15 mg weekly) over 72 weeks — the largest weight loss from any drug trial
- •Superior to semaglutide in the SURPASS-2 head-to-head trial for both HbA1c reduction and weight loss
- •36% of patients on the highest dose achieved 25% or greater body weight reduction
- •First dual GLP-1/GIP agonist approved — demonstrating that dual incretin targeting is superior to GLP-1 alone
- •Significant improvements in cardiovascular risk factors: blood pressure, triglycerides, and inflammatory markers
- •Ongoing trials for NASH, heart failure with preserved ejection fraction, and obstructive sleep apnea
Research Dosage Protocols
Tirzepatide is FDA-approved with a dose titration schedule: 2.5 mg weekly for 4 weeks, then 5 mg, then 7.5 mg, then 10 mg, then 12.5 mg, with a maximum of 15 mg weekly. Each dose is maintained for at least 4 weeks before escalation.
Research-grade tirzepatide is supplied as lyophilized powder requiring reconstitution. Like semaglutide, researchers should note that compounded and research-grade formulations lack the pharmaceutical-grade quality controls of Mounjaro/Zepbound.
The most common side effects are gastrointestinal: nausea, diarrhea, decreased appetite, vomiting, and constipation. These are dose-dependent and typically improve with continued use and proper titration.
For research reference only. Not medical advice. Not for human consumption.
Published Research (2 studies)
- [1]Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1)— Jastreboff et al., NEJM 2022PMID: 35658024
- [2]Tirzepatide versus semaglutide in type 2 diabetes (SURPASS-2)— Frias et al., NEJM 2021PMID: 34170647
Links go to PubMed (NIH National Library of Medicine). PeptideVerdict is not affiliated with these studies.
Price Comparison (9 products from 3 vendors)
| Vendor | Price | Stock |
|---|---|---|
| Paradigm Peptides | $149.00 $4.97/mg 30mg lyophilized | In Stock |
| Paradigm Peptides | $300.00 $5.00/mg 60mg lyophilized | In Stock |
| Polaris Peptides | $360.00 $6.00/mg 60mg lyophilized | In Stock |
| Polaris Peptides | $320.00 $6.40/mg 50mg lyophilized | Out |
| Peptide Partners | $297.00 $7.42/mg 40mg | In Stock |
| Paradigm Peptides | $80.00 $8.00/mg 10mg lyophilized | In Stock |
| Polaris Peptides | $250.00 $8.33/mg 30mg lyophilized | In Stock |
| Polaris Peptides | $99.00 $9.90/mg 10mg lyophilized | In Stock |
| Polaris Peptides | $55.00 $11.00/mg 5mg lyophilized | In Stock |
Frequently Asked Questions
What is tirzepatide?
Tirzepatide is a dual GLP-1/GIP receptor agonist FDA-approved as Mounjaro (diabetes) and Zepbound (weight management). It activates two incretin pathways simultaneously, producing greater weight loss than single-target GLP-1 drugs.
How does tirzepatide compare to semaglutide?
Tirzepatide produced greater weight loss (22.5% vs 14.9%) and better blood sugar control in clinical trials. It activates both GLP-1 and GIP receptors, while semaglutide targets only GLP-1. However, semaglutide has more long-term safety data.
Where can I buy tirzepatide for research?
Research-grade tirzepatide is available from select peptide vendors. Compare pricing in the table above. Note availability may be limited due to high demand.